Followers | 35 |
Posts | 182 |
Boards Moderated | 0 |
Alias Born | 05/03/2020 |
Saturday, June 20, 2020 3:30:46 PM
I believe our mc will have a massive run to 400m to 600m... with the grant and phase II trial being announced. It seems that MODERATE cv19 is the ideal target. But if we get a bigger grant enough to run both mild and moderate, watch out World! I'm pegging our valuation to be trading close to $1.2b. It seems the version of nasal spray for mild case will be ideal if the oral version takes longer to produce.
Leo can possibly seek convertible preferreds for $10m to $20m in order to fund or just seek out PPF alternative and initiate a third and/or fourth phase II trials as well for severe and/or mild Cv19 patients. And on top of getting uplisted to NASDAQ.
I also believe that compassionate care usage of Bril in critically patients should be a great choice as a feeler to test the water first, before jumping straight to critically patients. But I tell you what, this Bril drug should work and will have a significant impact in reduced mortality rate! Going straight to critically ill patients will be a huge feat. A min 20% to 25% reduction in mortality rate will be statistically significant. Bril + ventilator vs Remde + ventilator for placebo. Lol.
After phase II results come back, then Leo can strike a deal with PFE if it makes business sense. Can you imagine having two or four cv19 pipelines?? And what that would do to our valuation? That's an easy $3b without phase II RESULTS coming out yet.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM